FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Oncology Drugs in Phase III Clinical Development in SPAIN

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

            Therapeutic Area: Oncology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2020

            Details:

            Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC) in the USA, Canada, Europe, Australia and now also in Japan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

            Therapeutic Area: Oncology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2020

            Details:

            Isofol's drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: $1,000.0 million Upfront Cash: $200.0 million

            Deal Type: Licensing Agreement January 22, 2020

            Details:

            PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.